You are here

  • Home
  • Archive
  • Volume 20, Issue Suppl 1
  • CPC-091 Natalizumab in Cypriot Patients with Relapsing Remitting Multiple Sclerosis: Three Year Data on Safety, Efficacy and Frequency of Anti-JC Virus Antibodies

Alerts

Article menu

Download PDFPDF

Clinical pharmacy and clinical trials (including case series)
CPC-091 Natalizumab in Cypriot Patients with Relapsing Remitting Multiple Sclerosis: Three Year Data on Safety, Efficacy and Frequency of Anti-JC Virus Antibodies
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address